Comparison Between Raloxifene and Bazedoxifene

Last updated: October 18, 2016
Sponsor: Toshihiko Kono
Overall Status: Trial Status Unknown

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT01973738
IRB TH 05
  • Ages 45-100
  • Female

Study Summary

Although there are two kinds of selective estrogen receptor modulator (SERM) :raloxifene (RLX) and bazedoxifene (BZA), the difference is still unclear. In this study, we plan to compare clinical efficacy and safety between RLX and BZA.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Postmenopausal women

Exclusion

Exclusion Criteria:

  • Patients who could not use SERM

Study Design

Total Participants: 300
Study Start date:
January 01, 2012
Estimated Completion Date:
December 31, 2018

Study Description

Selective estrogen receptor modulator (SERM) is an important option for postmenopausal osteoporosis. There are two SERM approved in Japan for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. One is raloxifene (RLX), and the other is bazedoxifene (BZA). There are few reports concerning to the clinical efficacy and safety data. In this study, we plan to compare clinical efficacy and safety between RLX and BZA.

The main objective of this study is to reveal the effects of RLX and BZA on bone mineral density, bone turnover markers, and bone quality markers.

Connect with a study center

  • Tomidahama Hospital

    Yokkaichi, Mie 510-8008
    Japan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.